Antihyperglycemic therapy in type 2 diabetes: general recommendations

Slides:

Advertisements

Similar presentations

Pathways – Dr Duncan Fowler

Advertisements

Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association.

Canadian Diabetes Association Clinical Practice Guidelines Treatment of Diabetes in People with Heart Failure Chapter 28 Jonathan G. Howlett, John C. MacFadyen.

The Role of DPP-IV Inhibitors in the Management of Type 2 Diabetes

Mapping Medications: a foundation for clinical decision support for diabetes Health Federation of Philadelphia February 29, 2016.

Copyright © 2015 by the American Osteopathic Association.

Taieb V, et al. Value Health Nov;18(7):A598.

2012 ADA Clinical Practice Guidelines Therapies for DM- Type 2

Copyright © 2015 by the American Osteopathic Association.

Recommendation In people with clinical cardiovascular disease in whom glycemic targets are not met, a SGLT2 inhibitor with demonstrated cardiovascular.

Stuart A. Ross, MB CHB, FRACP, FRCP(C)

SGLT2 Inhibitors: What Do the Data Mean for My Patients?

Global Projections for Diabetes:

Patient Case Discussions in T2D: What Intensification Plan Is Best?

Updates on Outcomes for Novel T2D Therapies

Program Goals. Consulting the Experts: Prandial Insulin or a GLP-1 Receptor Agonist as Add-On to Basal Insulin.

Clinical Advances in Type 2 Diabetes and Cardiovascular Risk

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Choosing glucose-lowering medication in those with established ASCVD, HF, and CKD. CV, cardiovascular; DPP-4i, dipeptidyl peptidase 4 inhibitor; GLP-1.

GLP-1 Receptor Agonists: How Early Is Appropriate?

A Deep Dive Into CVOTs.

Options for Combination Therapy in Type 2 Diabetes: Comparison of the ADA/EASD Position Statement and AACE/ACE Algorithm Timothy Bailey, MD The American.

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Integrated Diabetes Care: How Can We Make the Best Use of New Technology?

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Case Study Role of DPP-4 Inhibitors

2008 FDA Guidance. Working as a Team for Cardiovascular Risk Reduction in Patients With T2D.

Early and Intensive T2D Management:

Improving Appropriate Access to PCSK9 Inhibitors

Injectable Options as Add-Ons to Basal Insulin: Targeting PPG in Type 2 Diabetes Patients.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (17). Antihyperglycemic therapy in type 2 diabetes: general recommendations (17).

Average patient profile in terms of (A) previous therapy drug class and (B) complexity of previous regimen. Average patient profile in terms of (A) previous.

LEADER One Year On.

RCHC’s Cardiovascular Health Initiative

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Antihyperglycemic Therapy

Antihyperglycemic therapy in type 2 diabetes: general recommendations.

Individualizing Insulin Therapy in the Management of Type 2 Diabetes

Case Challenges: Early and Intensive Type 2 Diabetes Treatment With Modern Agents.

Approach to starting and adjusting insulin in type 2 diabetes.

Oral Combination Therapy for T2D

Changes in A1C (A), body weight (B), and systolic blood pressure (C) with canagliflozin in combination with incretin-based therapies. *In the dose-advancement.

Patient Selection for Modern T2D Agents

Trends in the relative contribution of each second-line diabetes medication class, by quarter, as a percent of all second-line prescribing, 2011–2015.

Improving Overall Health

Kaplan-Meier plot of incident CVD according to the treatment group over a 4-year period following intensification of diabetes therapy. Kaplan-Meier plot.

ADA/EASD general recommendations for type 2 diabetes management (1).

Range of mean changes from baseline in A1C in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor agonists.

Range of mean changes from baseline in body weight in clinical studies of 24–52 weeks’ duration reported in prescribing information for five GLP-1 receptor.

The rates of occurrences of cardiovascular, cerebrovascular, and all events expressed in cases per 1, 000 patient-years in diabetic subgroups divided by.

Glucose-lowering medication in type 2 diabetes: overall approach.

Mechanisms of metformin in humans.

The concept of immortal time bias is depicted schematically using the cohort study from the Taiwanese National Health Insurance data during 2000–2007:

Observed RW, modeled, and published trial estimates of HbA1c change from baseline. Observed RW, modeled, and published trial estimates of HbA1c change.

What's New in Oral Combination Therapy for Type 2 Diabetes?

Patient flowchart of recruitment and treatment failure and success with glyburide vs. metformin. Patient flowchart of recruitment and treatment failure.

Multilevel Intervention Most scientific proof about developing health and health patronage.

Antihyperglycemic therapy in type 2 diabetes: general recommendations (22). Antihyperglycemic therapy in type 2 diabetes: general recommendations (22).

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or angiotensin receptor blocker (ARB) is.

Study design (A) and patient disposition (B).

Risk Stratification of Patients With Type 2 Diabetes: An Interpretation of the Latest Treatment Guidelines.

Prevalence of prescribing of different anti-diabetic medications as add-on therapy in patients with type 2 diabetes on metformin. *Other=Sum of prevalence.

Pooled estimate of relative risk and 95% CIs of colorectal cancer associated with metformin therapy based on four studies comprising 107,961 diabetic patients.

Antihyperglycemic therapy in adults with type 2 diabetes

Effects of metformin on GLP-1(7–36)amide degradation in vitro shown by GLP-1(7–36)amide concentrations (% variation from time 0) after a 30-min incubation.

Recommendations for the treatment of confirmed hypertension in people with diabetes. *An ACE inhibitor (ACEi) or ARB is suggested to treat hypertension.

Guideline approach to drug therapy in newly diagnosed type 2 diabetic patients not at target. Guideline approach to drug therapy in newly diagnosed type.

Glucose-lowering medication in type 2 diabetes: overall approach.

Fig. 1. Antihyperglycemic therapy algorithm for adult patients with type 2 diabetes mellitus (T2DM). The algorithm stratifies the choice of medications.

Presentation transcript:

Antihyperglycemic therapy in type 2 diabetes: general recommendations Antihyperglycemic therapy in type 2 diabetes: general recommendations. *If patient does not tolerate or has contraindications to metformin, consider agents from another class in Table 8.1. #GLP-1 receptor agonists and DPP-4 inhibitors should not be prescribed in combination. Antihyperglycemic therapy in type 2 diabetes: general recommendations. *If patient does not tolerate or has contraindications to metformin, consider agents from another class in Table 8.1. #GLP-1 receptor agonists and DPP-4 inhibitors should not be prescribed in combination. If a patient with ASCVD is not yet on an agent with evidence of cardiovascular risk reduction, consider adding. American Diabetes Association Dia Care 2018;41:S73-S85 ©2018 by American Diabetes Association